inflammatory bowel disease
RedHill Biopharma to Launch Phase II Trial of Crohn's Disease Drug in Biomarker-Defined Population
The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.
Nordic Bioscience Gets FDA Letter of Support for CPa9-HNE Biomarker in IBD
The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.
Australia's Colonial Foundation Commits A$21M for Inflammatory Disease Dx Research Center
The new center will use spatial omics technology and be led by the Royal Melbourne Hospital and the Walter and Eliza Hall Institute of Medical Research (WEHI).
C4X Discovery to Use Genetic Signature to Predict IBD Treatment Response in Clinical Trials
The company recently discovered this gene signature in a large dataset of patients treated with a marketed a4β7 integrin antibody for ulcerative colitis.
Wellcome Sanger Institute, Open Targets Fund Inflammatory Bowel Disease Biomarker Study
Researchers will analyze multiomic and clinical data from 1,000 patients with IBD recruited from seven participating hospitals in the UK.